Combination of phosphodiesterase‐5 inhibitors and α‐blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
- 23 February 2006
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 97 (s2) , 39-43
Abstract
As the prevalence of both erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) increases with age, physicians could be in the position to manage these two conditions simultaneously. Moreover, medical therapies for either one of these conditions can affect the other and this should be carefully considered when making treatment decisions. Pharmacotherapy for benign prostatic hyperplasia (BPH)/LUTS can cause side‐ effects affecting sexual function. Hence, 5α‐reductase inhibitors such as finasteride and dutasteride are associated with a greater risk of ED, ejaculatory disorders (EjD) and decreased libido than is placebo. Among α 1 ‐adrenergic blockers, tamsulosin is associated with an increased risk of EjD. However, some α 1 ‐adrenergic blockers can also have a positive impact on erection. This is the case for alfuzosin, which has been shown to enhance erectile function in experimental models, probably by reducing the sympathetic tone and thus relaxing corpus cavernosum smooth muscle cells. Phosphodiesterase 5 (PDE‐5) inhibitors are commonly used to treat ED. There is increasing evidence that they might also have a beneficial effect on LUTS, probably through the nitric‐oxide pathway. Nitric oxide is an important mediator of the relaxation of isolated bladder and urethral smooth muscle, and could modulate prostatic smooth muscle tone. α 1 ‐adrenergic blockers and PDE‐5 inhibitors can therefore have a positive impact on both ED and LUTS. Although placebo‐controlled studies are needed to confirm the impact of these drugs, alone or combined, on both ED and LUTS, this reinforces the need for a common approach to managing these two highly prevalent and bothersome conditions.Keywords
This publication has 20 references indexed in Scilit:
- Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiologyBJU International, 2006
- Long‐term efficacy and safety of alfuzosin 10 mg once daily: a 2‐year experience in ‘real‐life’ practiceBJU International, 2006
- Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunctionBJU International, 2005
- Efficacy of extended‐release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunctionBJU International, 2004
- INTERACTION BETWEEN THE PHOSPHODIESTERASE 5 INHIBITOR, TADALAFIL AND 2 α-BLOCKERS, DOXAZOSIN AND TAMSULOSIN IN HEALTHY NORMOTENSIVE MENJournal of Urology, 2004
- Alfuzosin Improves Penile Erection Triggered by Apomorphine in Spontaneous Hypertensive RatsEuropean Urology, 2004
- AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment RecommendationsJournal of Urology, 2003
- Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’International Journal Of Impotence Research, 2000
- Long-term Effects on Sexual Function of Five Antihypertensive Drugs and Nutritional Hygienic Treatment in Hypertensive Men and WomenHypertension, 1997
- Cigarette smoking and prostatism: A biphasic association?Urology, 1994